Last reviewed · How we verify
NCT06259045: CACH-IT-AHF
Cardiac Cachexia in Advanced Heart Failure
trial in Advanced Heart Failure in 200 participants. Status unknown.
1 September 2025
Quick facts
| Lead sponsor | Royal Brompton & Harefield NHS Foundation Trust |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 25 January 2024 |
| Primary completion | 1 September 2025 |
| Estimated completion | 1 November 2025 |
| Sites | 1 location across United Kingdom |
Conditions studied
- Advanced Heart Failure — all drugs for Advanced Heart Failure →
- Cardiac Cachexia — all drugs for Cardiac Cachexia →
- Weight Loss — all drugs for Weight Loss →
Sponsor
Royal Brompton & Harefield NHS Foundation Trust
Who can join
18 and older, any sex, with Advanced Heart Failure or Cardiac Cachexia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Heart failure is a condition in which the heart stops pumping effectively, causing symptoms such as breathlessness or leg swelling. It affects around 900,000 people in the United Kingdom. As our population gets older, this number will continue rise. It is a condition with poor overall survival - nearly 50% of patients die within 5 years of being diagnosed with heart failure. Cardiac cachexia is a complex condition associated with heart failure. There is general loss of muscle with or without loss of fat in cardiac cachexia. The main feature of cardiac cachexia is therefore unintentional weight loss in heart failure patients. The reason why it develops is poorly understood currently. Importantly, some studies have shown that cardiac cachexia is more likely to lead to poorer outcomes (such as death) in the patients who develop it. However, there have been no studies, to our knowledge, that look at this condition in those patients who have very weak hearts ('advanced heart failure'). The investigators are looking to clarify how common cardiac cachexia is within advanced heart failure patients, and secondly how outcomes compare to those advanced heart failure patients that do not have the condition. With this in mind, the investigators will be able to establish the fuller impact cardiac cachexia has on survival and outcomes in patients with advanced heart failure. This study will involve assessing a group of \~200 advanced heart failure patients for cardiac cachexia to establish an estimate of how common it is overall. The investigators will then follow up the patients over a year, to see if we can assess the impact of cardiac cachexia on survival and outcomes. Overall, the investigators therefore hope this study will give a more robust picture on the true impact of cardiac cachexia in advanced heart failure. By doing so, the investigators will firstly highlight its importance to other clinicians who will better be able to monitor and or diagnose it, and secondly pave way for more research on a potential treatment strategy for this condition.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06259045
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Heart Failure
Currently open trials in the same condition.
- NCT07497308 — GDF-15 and Early Outcomes After LVAD Implantation · recruiting
Other Royal Brompton & Harefield NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07502677 — Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Scle · recruiting
- NCT07498842 — Corticosteroid Tapering in Sarcoidosis · NA · recruiting
- NCT07402434 — A Prospective Study of Advanced Diagnostics in People With an Unclear Diagnosis of Cystic Fibrosis · not yet recruiting
- NCT06661278 — Evaluation of Exercise Testing and Physical Activity in Children and Adolescents Living With Inherited Arrhythmias · recruiting
- NCT06519240 — A Pilot Study Evaluating the Potential of 18F Fluorodeoxyglucose PET-CT Imaging in Diagnosing Cardiac Rejection. · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06259045 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Royal Brompton & Harefield NHS Foundation Trust
- Last refreshed: 14 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06259045.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing